2024 | Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study
| LIVER CANCER |
2024 | Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”
| CLINICAL AND MOLECULAR HEPATOLOGY |
2024 | Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents | LIVER INTERNATIONAL |
2024 | Regulation of Tumor Microenvironment through YAP/TAZ under Tumor Hypoxia
| CANCERS |
2024 | Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
| YONSEI MEDICAL JOURNAL |
2024 | Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
| CLINICAL AND MOLECULAR HEPATOLOGY |
2024 | Liver-Directed Combined Radiation Therapy for Downstaging Beyond-Milan Hepatocellular Carcinoma to Liver Transplantation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
2024 | Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study | JOURNAL OF HEPATOLOGY |
2024 | Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
2024 | Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY |
2024 | Machine learning-based clinical decision support system for treatment recommendation and overall survival prediction of hepatocellular carcinoma: a multi-center study
| NPJ DIGITAL MEDICINE(Nature partner journals digital medicine Digital medicine) |
2024 | Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea
| GUT AND LIVER |
2023 | Impact of Low Skeletal Muscle Mass on Long-Term Outcomes in Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization: A Retrospective Multi-Center Study
| CANCERS |
2023 | Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
| CELL COMMUNICATION AND SIGNALING |
2023 | MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
2023 | ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
2023 | Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
2023 | A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B | LIVER INTERNATIONAL |
2023 | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | AMERICAN JOURNAL OF GASTROENTEROLOGY |
2023 | Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
| CLINICAL AND MOLECULAR HEPATOLOGY |
2023 | Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
| CLINICAL AND MOLECULAR HEPATOLOGY |
2023 | Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria
| CANCER RESEARCH AND TREATMENT |
2023 | The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
2023 | Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
| CLINICAL AND MOLECULAR HEPATOLOGY |
2023 | Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
| CLINICAL AND MOLECULAR HEPATOLOGY |
2023 | Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease | LIVER INTERNATIONAL |
2023 | Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
| CANCER MEDICINE |
2023 | Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY |
2023 | Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
| DIAGNOSTICS |
2023 | Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Dise | GUT AND LIVER |
2022 | Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology
| Journal of Liver Cancer(대한간암학회지) |
2022 | Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
| GUT AND LIVER |
2022 | Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model
| GASTROENTEROLOGY REPORT |
2022 | Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B | DIGESTIVE DISEASES AND SCIENCES |
2022 | A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoxetic Acid-Enhanced MRI Features | JOURNAL OF MAGNETIC RESONANCE IMAGING |
2022 | Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization | CLINICAL NUCLEAR MEDICINE |
2022 | Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone | CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT |
2022 | Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study | LANCET GASTROENTEROLOGY & HEPATOLOGY |
2022 | Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS)
| CANCERS |
2022 | Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
| CANCERS |
2022 | Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways
| BMC CANCER |
2022 | Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
| FRONTIERS IN MEDICINE |
2022 | Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
2022 | Cost-effectiveness of chronic hepatitis C screening and treatment
| CLINICAL AND MOLECULAR HEPATOLOGY |
2022 | Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study | JOURNAL OF VIRAL HEPATITIS |
2022 | Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma
| JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
2022 | A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
| JOURNAL OF KOREAN MEDICAL SCIENCE |
2022 | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
| CANCERS |
2022 | Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
| GUT AND LIVER |
2022 | Liver-directed concurrent chemoradiotherapy versus sorafenib in hepatocellular carcinoma with portal vein tumor thrombus | JOURNAL OF CLINICAL ONCOLOGY |